Physician profile
Carmen Escaba
NPI 1932872959
$2,430.09
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,270 · 2022: $835 · 2023: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $886.10 | 2021 | |
| Abbvie INC. | $298.89 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $197.60 | 2022-2023 | |
| Intra-Sana Laboratories | $159.19 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Redhill Biopharma INC. | $134.71 | 2021-2022 | |
| Novo Nordisk INC | $127.83 | 2021-2023 | Wegovy |
| Astellas Pharma US INC | $99.99 | 2021 | |
| Lilly USA, LLC | $94.70 | 2022 | |
| Esperion Therapeutics, INC. | $78.99 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.09 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.51 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $46.06 | 2022-2023 | Imcivree |
| Bayer Healthcare Pharmaceuticals INC. | $39.29 | 2021 | |
| Janssen Pharmaceuticals, INC | $31.03 | 2022 | |
| Currax Pharmaceuticals LLC | $28.53 | 2021-2023 | Contrave |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $24.37 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $20.21 | 2021 | |
| Ibsa Pharma INC. | $18.67 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.36 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Escaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.